21 and older, any sex, with Tobacco Use Disorder. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Demand IntensityPrimary· Four times over approximately two weeks
Consumption of cigarettes at unconstrained price as measured by an incentivized demand task. Minimum value is 0, maximum value is not constrained. Higher scores indicate more cigarette consumption at unconstrained price (a worse outcome).
Condition A: Told Full, Received Reduced
Group
Value
95% CI
Subjects Included in Analysis
6.48
± 4.55
Condition B: Told Full, Received Full
Group
Value
95% CI
Subjects Included in Analysis
8.10
± 6.61
Condition C: Told Reduced, Received Full
Group
Value
95% CI
Subjects Included in Analysis
7.81
± 5.63
Condition D: Told Reduced, Received Reduced
Group
Value
95% CI
Subjects Included in Analysis
6.48
± 4.91
Demand ElasticityPrimary· Four times over approximately two weeks
Changes in cigarette consumption with changes in price as measured by an incentivized demand task. There is no minimum or maximum value. Higher scores indicate greater cigarette price sensitivity (a better outcome). Values are log-transformed. Data are presented for all subjects with non-zero data (zero data cannot be analyzed with a demand function so elasticity cannot be generated)
Condition A: Told Full, Received Reduced
Group
Value
95% CI
Subjects Included in Analysis
-1.31
± 1.08
Condition B: Told Full, Received Full
Group
Value
95% CI
Subjects Included in Analysis
-1.45
± 0.50
Condition C: Told Reduced, Received Full
Group
Value
95% CI
Subjects Included in Analysis
-1.57
± 0.60
Condition D: Told Reduced, Received Reduced
Group
Value
95% CI
Subjects Included in Analysis
-1.26
± 1.17
Minnesota Nicotine Withdrawal ScaleSecondary· Post-cigarette administration four times over approximately two weeks
A subjective effect measure of nicotine withdrawal. Minimum value is 0, maximum value is 68. Higher scores indicate greater nicotine withdrawal (a worse outcome).
Condition A: Told Full, Received Reduced
Group
Value
95% CI
Subjects Included in Analysis
5.67
± 6.95
Condition B: Told Full, Received Full
Group
Value
95% CI
Subjects Included in Analysis
5.14
± 6.54
Condition C: Told Reduced, Received Full
Group
Value
95% CI
Subjects Included in Analysis
4.33
± 4.95
Condition D: Told Reduced, Received Reduced
Group
Value
95% CI
Subjects Included in Analysis
6.24
± 6.47
Sponsor's own description
The goal of this project is to experimentally evaluate how expectations about reduced-nicotine cigarettes as well as actual nicotine content interact to determine behavioral and subjective response for these novel products.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins University
Last refreshed: 9 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04999644.